1 / 15

Gaucher Disease

Gaucher Disease. A Closer Look Ray Molzon. Introduction. Lysosomal storage disease (Sphingolipidose) Deficiency of glucocerebrosidase causes buildup of glucocerebroside Gaucher cells, store sphingolipid in spleen, liver, bone marrow, alveolar spaces, brain tissue. Symptoms. Anemia

alfonso-blackwell
Download Presentation

Gaucher Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gaucher Disease A Closer Look Ray Molzon

  2. Introduction • Lysosomal storage disease (Sphingolipidose) • Deficiency of glucocerebrosidase causes buildup of glucocerebroside • Gaucher cells, store sphingolipid in spleen, liver, bone marrow, alveolar spaces, brain tissue

  3. Symptoms • Anemia • Reduced platelet count • Bone demineralization • Jaundice • Hepatosplenomegaly • Neurologic effects (ataxia, seizures, …)

  4. Diagnosis • Three recognized types: • Type I (Noncerebral juvenile) • Most common in Ashkenazi Jew lineage (1:450) • Type II (Infantile cerebral) • 1 in 100,000 live births • Death usually occurs w/in 1 year • Type III (Chronic neuropathic/Norbottnian) • 1 in 50,000 live births

  5. The Gene • GBA • Located on 1q21 • 11 exons, mRNA 1610bp • Potential promoters: 2 TATA & 2 CAT • 2 ATG start sites, both equally efficient • GBAP • Located ~16kb downstream of GBA

  6. The Enzyme • Reaction catalyzed: • D-glucosyl-N-acylsphingosine + H2O <=> D-glucose + N-acylsphingosine • 536 peptides • Signal peptide: 1-39aa • Glu235 (acid/base catalyst) and Glu340 (nucleophile) predicted to be in active region • 5 potential glycosylation sites • Member of O-glycosyl hydrolase 30 family

  7. Mutations • Over 150 GBA mutations identified • Not all proven to cause disease • 4 account for disease in 95% of Ashkenazi Jewish population, 50% of general pop. • Many found to be identical to mutations in pseudogene

  8. L444P • Single bp substitution in exon 10 • Produces new cleavage site for NCiI endonuclease • Protein has only 497 aa • Same mutation in GBAP • Homozygosity associated w/ Type III • Found to be cause of Norbottnian subtype • Recombinant allele found w/ Type II

  9. N370S • Single bp (A to G) in exon 9 • Found only in Type I patients • Gene frequency of .035 in Ashkenazi • Much rarer in general population • Appears to prevent neuropathic symptoms in patients with L444P allele

  10. 84GG • Insertion mutation of G at cDNA 84 • Also very common in Ashkenazi population • N370S found to have .957 linkage disequilibrium w/ neighboring PKLR A1 allele • 84GG has 1.00 linkage disequilibrium w/ A6 allele of PKLR • Supports hypothesis that both mutations originated in individual founders

  11. IVS2 • Single bp substitution in splice donor site of intron 2 • Causes skipping of exon 2 • Accounts for .034 of disease alleles in Ashkenzaki • 84GG & IVS2 both result in no enzyme

  12. Treatment • Splenectomy (rarely cures) • Gene therapy • Enzyme replacement • Placental glucorcerebrosidase (Ceredase) • $382,200/year for 70kg patient! • Bone marrow transplantation • Treatment of choice in advanced disease • Chemical chaperone treatment • Found to aid folding of N370S mutation

  13. Phylogeny

  14. Tidbits • Pseudogene is recent in evolutionary history

  15. References • Obtained medical info from various sources: • Obtained genetic/molecular info from: • Used GCG for sequence comparisons

More Related